ストックスクリーナーアプリを入手
10.34
2.36%
-0.25
プレマーケット:
10.60
0.26
+2.51%
Cartesian Therapeutics Inc (RNAC) 最新ニュース
RNACCartesian Therapeutics Inc Latest SEC Filings - Finviz
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Pipeline AdvancesOne-Time Gain Impact - dars.gov.et
Price to earnings forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
RNAC Forecast — Price Target — Prediction for 2027 - TradingView
Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC) - TradingView
Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Price to book forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cartesian Therapeutics Shareholders Back Directors and Governance Measures - The Globe and Mail
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cartesian Therapeutics Inc (RNAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Institutional Confidence - TradingKey
Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor - Stock Titan
Cartesian Therapeutics Inc (RNAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) ChartsRNAC - GuruFocus
Cartesian Therapeutics (RNAC) Slides 7.2% as Support Nears $8.38Corrective Wave - newsline.com
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
New partnership gives Cartesian Therapeutics another shot at autoimmune disease market - MSN
RNAC Q1 2026 Earnings: Disappointing EPS Miss Yet Stock Surges 18%Earnings Weakness Phase - newsline.com
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
New hire at Cartesian gets 6,100 stock options vesting to 2030 - Stock Titan
Cartesian climbs on licensing deal with WestGene for CAR-T therapies - MSN
RNAC: Directors elected and all proposals passed with strong support; no stockholder questions submitted - TradingView
Cartesian Therapeutics, Inc. (RNAC) soars 10.3%: Is further upside left in the stock? - MSN
Cartesian Eyes Multiple 2026-2027 Readouts As Descartes-08 Advances Toward Potential BLA - RTTNews
RNAC Reiterated by Wedbush -- Price Target Maintained at $38.00 - GuruFocus
RNAC Reiterated by BTIG -- Price Target Maintained at $44.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cartesian Therapeutics (RNAC) and Abbott Laboratories (ABT) - The Globe and Mail
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Announces Target Price $40 - Moomoo
Morgan Stanley Smith Barney (RNAC) lists exercises, vesting and a 3,924-share resale - Stock Titan
RNAC Reiterated by Needham -- Price Target Maintained at $40 - GuruFocus
Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre - GuruFocus
WestGene Biopharma to collaborate with Cartesian Therapeutics on in vivo CAR-T for autoimmune disease - Traders Union
Cartesian partners with WestGene for in vivo autoimmune CAR-T - grafa.com
Cartesian inks licensing deal with WestGene (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics stock jumps on WestGene partnership deal - Investing.com UK
Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com - Investing.com Australia
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance - TipRanks
Cartesian strikes licensing agreement with WestGene - The Pharma Letter
Cartesian Therapeutics | 8-K: Current report - Moomoo
Cartesian Therapeutics (RNAC) licenses in vivo CAR-T delivery tech from WestGene - Stock Titan
Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases - TradingView
Experimental in vivo CAR-T for myasthenia gravis could skip lab manufacturing - Stock Titan
Cartesian Therapeutics (RNAC) Slides 10.8% as Stock Tests Key Support LevelsVol Target Rebalance - newsline.com
Cartesian Therapeutics (RNAC) Faces Sharp Decline, Testing Key Support LevelsADD Alert - newsline.com
[144] Cartesian Therapeutics, Inc. SEC Filing - Stock Titan
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):